Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Genetics don't change the game for resmetirom. A new secondary analysis of a phase 3 trial found that resmetirom — the only FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) — delivered consistent improvements in liver health regardless of a patient's genetic risk profile. The findings suggest the drug's benefits extend broadly across the MASH population, even among those with high-risk gene variants linked to more severe liver disease.
Genetics don't change the game for resmetirom
A new secondary analysis of a phase 3 trial found that resmetirom — the only FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) — delivered consistent improvements in liver health regardless of a patient's genetic risk profile. Researchers analyzed 738 patients with biopsy-confirmed MASH and fibrosis, grouping them by variants in five genes known to influence liver disease severity: PNPLA3, HSD17B13, TM6SF2, MTARC1, and MBOAT7.
Across all genetic subgroups, resmetirom outperformed placebo in MASH resolution, fibrosis improvement, and liver fat reduction at week 52 — with no significant interaction between genetic risk scores and treatment response. Notably, patients with high-risk PNPLA3 genotypes had fewer traditional metabolic risk factors (like diabetes and hypertension) at baseline, suggesting genetics may drive fibrosis through distinct pathways.
By the Numbers
Why it matters: These findings support resmetirom's broad applicability across genetically diverse MASH patients, giving clinicians confidence that genetic testing results shouldn't limit treatment decisions for this serious liver disease.
